Highlights

• Pathkey.AI (ASX:PKY) closed at AUD 0.038 on 18 August 2026, down 2.56%.
• S&P/ASX 200 Info Tech (ASX:XIJ) closed at 1,956.80 points, down 1.02% today.
• Chipforge Acquisition completed for AI semiconductor design technology.
• Cash balance was AUD 3.41 million at 30 June 2026.

Pathkey.AI Limited (ASX:PKY) closed at AUD 0.038 on 18 August 2026, declining 2.56% during the trading session. The movement occurred during a weaker session for technology stocks, with investors assessing the company’s expanded AI strategy following the Chipforge acquisition and continued development of its TrialKey platform.

The broader Australian market recorded lower trading levels, with the S&P/ASX 200 (ASX:XJO) closing at 9,070.00 points, down 0.035% today, while the S&P/ASX 300 (ASX:XKO) closed at 9,004.90 points, down 0.037% today.

The S&P/ASX 200 Info Tech (ASX:XIJ) closed at 1,956.80 points, down 1.02% today.

A daily share price movement does not necessarily indicate a change in a company’s underlying fundamentals. Investors generally assess AI technology development, commercial adoption, intellectual property, platform revenue, acquisitions and cash position when reviewing emerging technology companies.

Agentic AI technology platform

Pathkey.AI develops artificial intelligence platforms focused on data processing, decision support and automation.

The company operates two key technology platforms: TrialKey and Chipforge.

TrialKey is an AI-driven clinical trial optimisation platform designed to analyse clinical and regulatory information, support trial design decisions and improve research workflows.

Chipforge is an AI-powered semiconductor hardware design and development platform acquired by Pathkey.AI in 2026. The platform is designed to automate aspects of custom chip development by translating high-level design requirements into verified hardware code.

The company’s strategy combines AI applications across healthcare technology and semiconductor design, with a focus on building proprietary AI capabilities and commercialising technology platforms.

Investors generally monitor Pathkey.AI through platform adoption, commercial contracts, technology validation, intellectual property development, Revenue growth and funding position.

June 2026 update and Chipforge acquisition progress

Pathkey.AI released its June 2026 Quarterly Activities Report on 31 July 2026, highlighting completion of the acquisition of 100% of Chipforge, an AI-driven semiconductor hardware design and development technology platform.

The company stated that Chipforge’s AI-native platform is designed to translate high-level design intent into verified, synthesisable hardware code, targeting automation of custom semiconductor development through a single workflow. The platform uses AI agents and custom models to support hardware design, verification, simulation and implementation processes.

During the quarter, Pathkey.AI signed a Memorandum of Understanding with Inturai Ventures Corp to explore building drone-swarm command and control capabilities directly on edge silicon using Chipforge’s AI-powered chip design platform.

TrialKey continued commercialisation activities during Q4 FY26. The platform generated AUD 30,000 in revenue during the quarter, including AUD 25,000 from the initial phase of the Imunexus Therapeutics Limited engagement and AUD 5,000 from Armstrong Clinical.

The company also reported that TrialKey’s live portfolio was built on a dataset covering 3,434 clinical and regulatory events. During the quarter, TrialKey progressed a clinical trial scenario-optimisation engine and a Natural Language Processing (NLP)-based tool for monitoring public trial data in real time.

Pathkey.AI reported cash of AUD 3.41 million at 30 June 2026, including approximately AUD 870,000 received from option exercises. The company continues participating in Research and Development (R&D) Tax Incentive programs to generate cash offsets for development activities across Chipforge and TrialKey.

Earlier in FY26, Pathkey.AI completed a Capital raising of AUD 3.5 million and advanced TrialKey toward a scalable AI-driven decision-support platform. The company also secured a commercial contract with Imunexus Therapeutics with potential revenue of up to AUD 100,000 plus GST.

Factors investors generally monitor

For Pathkey.AI, technology commercialisation remains a key area of focus. Investors monitor whether AI platforms progress from development stages into commercial applications.

Chipforge development is another important consideration. Semiconductor design automation requires technology validation, customer adoption and industry partnerships before reaching broader commercial scale.

TrialKey adoption is also closely monitored. Investors assess whether clinical organisations and biotechnology companies adopt the platform for research optimisation and decision support.

Commercial contracts remain important because emerging technology companies require customer validation and Recurring Revenue pathways.

Intellectual property development is another factor. Investors monitor Patent protection, technology differentiation and the company’s ability to build proprietary AI capabilities.

Cash management remains relevant as Pathkey.AI invests across multiple technology platforms. Investors assess liquidity, R&D expenditure and future funding requirements.

Understanding the share price movement

Pathkey.AI shares declined 2.56% on 18 August 2026, reflecting trading activity during the session. Short-term share price movements can occur due to investor sentiment, technology sector trends, market positioning and expectations around future commercial progress.

A single trading day’s movement does not independently confirm a change in the company’s operational performance or financial outlook. Investors generally review technology milestones, commercial agreements, platform development and financial position when assessing emerging technology companies.

For Pathkey.AI, investor attention remains focused on Chipforge integration, TrialKey commercialisation and the company’s broader AI technology strategy.

AI technology sector outlook

Artificial intelligence continues expanding across industries, with companies developing solutions for automation, decision support, healthcare research and semiconductor design.

AI technology providers are generally assessed on their ability to build differentiated platforms, secure commercial partnerships and convert technical capability into scalable revenue opportunities.

Pathkey.AI’s dual focus on healthcare AI and semiconductor design provides exposure to multiple technology themes. However, future performance remains influenced by technology development timelines, customer adoption, commercial execution and funding requirements.

Investor focus is likely to remain on Chipforge customer engagement, TrialKey revenue growth, AI platform development and progress towards commercial scalability.

Conclusion

Pathkey.AI (ASX:PKY) closed at AUD 0.038 on 18 August 2026, down 2.56% during the session. The company continues developing AI platforms across semiconductor design automation and clinical trial optimisation.

The June 2026 update highlighted completion of the Chipforge acquisition, AUD 30,000 in TrialKey revenue during the quarter, an AUD 3.41 million cash balance and ongoing development of AI-based technology platforms. While daily share price movements reflect market activity, they do not alone indicate changes in underlying Business fundamentals. Investors continue to monitor AI commercialisation, technology validation, customer adoption and funding position.